Kozawa T, Sone H, Okuda Y, Kawakami Y, Sekine Y, Imai M, Hommura S, Inatomi M, Yaguchi S, Matsuo K, Segawa T, Suzuki H, Yamashita K
Kozawa Hospital, University of Tsukuba, Japan.
Nippon Ganka Gakkai Zasshi. 1998 Nov;102(11):731-8.
We determined the levels of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in the aqueous and serum in non-insulin dependent diabetic patients with proliferative retinopathy (n = 12) and neovascular glaucoma (n = 11). The aqueous levels of PEGF/VPF were significantly higher in both groups than in 10 diabetics without such complications. The levels were very high in patients with neovascular glaucoma, suggesting that VEGF/VPF is involved in the pathogenesis and progression of diabetic neovascular glaucoma. The serum levels were not significantly related to the presence or the stage of retinopathy. The findings suggest the possibility of treatment of neovascular glaucoma using anti- VRGF/VFP preparations.
我们测定了12例增殖性视网膜病变非胰岛素依赖型糖尿病患者及11例新生血管性青光眼患者房水和血清中血管内皮生长因子/血管通透因子（VEGF/VPF）的水平。两组患者房水中PEGF/VPF水平均显著高于10例无此类并发症的糖尿病患者。新生血管性青光眼患者的该水平非常高，提示VEGF/VPF参与糖尿病性新生血管性青光眼的发病机制和病情进展。血清水平与视网膜病变的存在与否及分期无显著相关性。这些发现提示使用抗VRGF/VFP制剂治疗新生血管性青光眼的可能性。
